# Riociguat for Sarcoidosis Associated Pulmonary Hypertension

> **NCT02625558** · PHASE4 · UNKNOWN · sponsor: **University of Cincinnati** · enrollment: 60 (estimated)

## Conditions studied

- Sarcoidosis

## Interventions

- **DRUG:** Riociguat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02625558
- **Lead sponsor:** University of Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-04
- **Primary completion:** 2018-04
- **Final completion:** 2018-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2015-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02625558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02625558, "Riociguat for Sarcoidosis Associated Pulmonary Hypertension". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02625558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*